TrialThe Journal of urology2023

Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).

Sandip M Prasad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.